Abstract
Background
Transarterial chemoembolization (TACE), one of the most commonly used postoperative adjuvant therapy for HCC, has achieved satisfactory outcomes. This study aimed to explore the prognostic value of lung immune prognostic index (LIPI) and develop a novel nomogram for recurrence-free survival (RFS) of HCC patients received postoperative adjuvant TACE (PA-TACE).
Methods
The prognostic value of LIPI was evaluated by C-index, receiver operating characteristic (ROC) analysis, and Kaplan–Meier survival curve. An effective nomogram based on preoperative prognostic factors was established from multivariate analysis and validated in the validation cohort.
Results
The ROC and survival analysis demonstrated that the LIPI exhibited better prediction performance of HCC recurrence than other inflammatory biomarkers. According to univariate and multivariate analysis, LIPI, followed by AFP, MVI and age, were significant independent predictors for HCC recurrence and were utilized to construct the nomogram. The C-indexes of the nomogram were 0.746 (95% CI 0.721–0.770) and 0.738 (95% CI 0.701–0.775) in the training and validation cohort, respectively. The AUCs for the 1-, 2-, and 3-year RFS were 0.799, 0.867 and 0.884 in the training cohort and 0.798, 0.779 and 0.770 in the validation cohort, respectively. The calibration curves presented good consistencies. Moreover, compared with the LIPI and other clinical staging system, the established nomogram presented better prognostic performance.
Conclusion
Preoperative LIPI might be a powerful predictor for RFS in HCC patients received PA-TACE. The LIPI-based nomogram could further effectively predict the risk of recurrence and help clinicians formulate personalized follow-up strategies and adjuvant therapy to improve patient outcomes.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE (2012) Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992–2008. Hepatology 55(2):476–482. https://doi.org/10.1002/hep.24710
Araki T, Tateishi K, Komatsu M, Sonehara K, Kanda S, Hanaoka M, Koizumi T (2022) Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy. Thorac Cancer 13(7):1006–1013. https://doi.org/10.1111/1759-7714.14349
Bishayee A (2014) The role of inflammation and liver cancer. Adv Exp Med Biol 816:401–435. https://doi.org/10.1007/978-3-0348-0837-8_16
Bower JE (2014) Cancer-related fatigue-mechanisms, risk factors, and treatments. Nat Rev Clin Oncol 11(10):597–609. https://doi.org/10.1038/nrclinonc.2014.127
Bruix J, Llovet JM (2002) Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 35(3):519–524. https://doi.org/10.1053/jhep.2002.32089
Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42(5):1208–1236. https://doi.org/10.1002/hep.20933
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338
Chen SH, Wan QS, Zhou D, Wang T, Hu J, He YT, Zhang KH (2019) A simple-to-use nomogram for predicting the survival of early hepatocellular carcinoma patients. Front Oncol 9:584. https://doi.org/10.3389/fonc.2019.00584
Chen MY, Juengpanich S, Hu JH, Topatana W, Cao JS, Tong CH, Cai XJ (2020) Prognostic factors and predictors of postoperative adjuvant transcatheter arterial chemoembolization benefit in patients with resected hepatocellular carcinoma. World J Gastroenterol 26(10):1042–1055. https://doi.org/10.3748/wjg.v26.i10.1042
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867. https://doi.org/10.1038/nature01322
Crusz SM, Balkwill FR (2015) Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 12(10):584–596. https://doi.org/10.1038/nrclinonc.2015.105
Diakos CI, Charles KA, McMillan DC, Clarke SJ (2014) Cancer-related inflammation and treatment effectiveness. Lancet Oncol 15(11):e493-503. https://doi.org/10.1016/s1470-2045(14)70263-3
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA (2013) Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 13(11):759–771. https://doi.org/10.1038/nrc3611
Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9(6):425–434. https://doi.org/10.1016/j.ccr.2006.04.023
Fitzgerald M, Saville BR, Lewis RJ (2015) Decision curve analysis. JAMA 313(4):409–410. https://doi.org/10.1001/jama.2015.37
Fukumoto T, Tominaga M, Kido M, Takebe A, Tanaka M, Kuramitsu K, Ku Y (2014) Long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion for multiple bilobar hepatocellular carcinoma. Ann Surg Oncol 21(3):971–978. https://doi.org/10.1245/s10434-013-3305-y
Galun D, Bogdanovic A, Djokic Kovac J, Bulajic P, Loncar Z, Zuvela M (2018) Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative-intent surgery for hepatocellular carcinoma: experience from a developing country. Cancer Manag Res 10:977–988. https://doi.org/10.2147/cmar.S161398
Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Fan J (2014) Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 20(23):6212–6222. https://doi.org/10.1158/1078-0432.Ccr-14-0442
Koukourakis MI, Giatromanolaki A, Sivridis E, Bougioukas G, Didilis V, Gatter KC, Harris AL (2003) Lactate dehydrogenase-5 (LDH-5) overexpression in non-small-cell lung cancer tissues is linked to tumour hypoxia, angiogenic factor production and poor prognosis. Br J Cancer 89(5):877–885. https://doi.org/10.1038/sj.bjc.6601205
Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38(3):207–215. https://doi.org/10.1007/s005350300038
Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156(2):477-491.e471. https://doi.org/10.1053/j.gastro.2018.08.065
Lee JG, Kang CM, Park JS, Kim KS, Yoon DS, Choi JS, Kim BR (2006) The actual 5-year survival rate of hepatocellular carcinoma patients after curative resection. Yonsei Med J 47(1):105–112. https://doi.org/10.3349/ymj.2006.47.1.105
Lin ZX, Ruan DY, Li Y, Wu DH, Ma XK, Chen J, Wu XY (2015) Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection. World J Gastroenterol 21(38):10898–10906. https://doi.org/10.3748/wjg.v21.i38.10898
Lin WF, Zhong MF, Zhang YR, Wang H, Zhao HT, Cheng BB, Ling CQ (2018) Prognostic role of platelet-to-lymphocyte ratio in hepatocellular carcinoma with different BCLC stages: a systematic review and meta-analysis. Gastroenterol Res Pract 2018:5670949. https://doi.org/10.1155/2018/5670949
Liu Y, You Y, Lu Z, Yang J, Li P, Liu L, Cao X (2019) N (6)-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication. Science 365(6458):1171–1176. https://doi.org/10.1126/science.aax4468
Liu H, Yang XL, Yang XY, Dong ZR, Chen ZQ, Hong JG, Li T (2021) The prediction potential of the pretreatment lung immune prognostic index for the therapeutic outcomes of immune checkpoint inhibitors in patients with solid cancer: a systematic review and meta-analysis. Front Oncol 11:691002. https://doi.org/10.3389/fonc.2021.691002
Ma L, Deng K, Zhang C, Li H, Luo Y, Yang Y, Xie C (2022) Nomograms for predicting hepatocellular carcinoma recurrence and overall postoperative patient survival. Front Oncol 12:843589. https://doi.org/10.3389/fonc.2022.843589
Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436–444. https://doi.org/10.1038/nature07205
Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, Besse B (2018) Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 4(3):351–357. https://doi.org/10.1001/jamaoncol.2017.4771
O’Rourke JM, Sagar VM, Shah T, Shetty S (2018) Carcinogenesis on the background of liver fibrosis: Implications for the management of hepatocellular cancer. World J Gastroenterol 24(39):4436–4447. https://doi.org/10.3748/wjg.v24.i39.4436
Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Mezquita L (2022) Predicting immunotherapy outcomes in older patients with solid tumors using the LIPI score. Cancers (basel). https://doi.org/10.3390/cancers14205078
Reig M, Cabibbo G (2021) Antiviral therapy in the palliative setting of HCC (BCLC-B and -C). J Hepatol 74(5):1225–1233. https://doi.org/10.1016/j.jhep.2021.01.046
Su K, Huang W, Li X, Xu K, Gu T, Liu Y, Han Y (2023) Evaluation of lactate dehydrogenase and alkaline phosphatase as predictive biomarkers in the prognosis of hepatocellular carcinoma and development of a new nomogram. J Hepatocell Carcinoma 10:69–79. https://doi.org/10.2147/jhc.S398632
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660
Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S (2015) Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 261(5):947–955. https://doi.org/10.1097/sla.0000000000000710
Wu J, Zhang H, Li L, Hu M, Chen L, Xu B, Song Q (2020) A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun (lond) 40(7):301–312. https://doi.org/10.1002/cac2.12067
Xia Z, Zhao Y, Zhao H, Zhang J, Liu C, Lu W, Shen A (2022) Serum alanine aminotransferase to hemoglobin ratio and radiological features predict the prognosis of postoperative adjuvant TACE in patients with hepatocellular carcinoma. Front Oncol 12:989316. https://doi.org/10.3389/fonc.2022.989316
Xie DY, Ren ZG, Zhou J, Fan J, Gao Q (2020) 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 9(4):452–463. https://doi.org/10.21037/hbsn-20-480
Xie DY, Zhu K, Ren ZG, Zhou J, Fan J, Gao Q (2023) A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr 12(2):216–228. https://doi.org/10.21037/hbsn-22-469
Xu L, Yu S, Zhuang L, Wang P, Shen Y, Lin J, Meng Z (2017) Systemic inflammation response index (SIRI) predicts prognosis in hepatocellular carcinoma patients. Oncotarget 8(21):34954–34960. https://doi.org/10.18632/oncotarget.16865
Yang Z, Ye P, Xu Q, Lu Y, Tang B, Wang Q, Chen X (2015) Elevation of serum GGT and LDH levels, together with higher BCLC staging are associated with poor overall survival from hepatocellular carcinoma: a retrospective analysis. Discov Med 19(107):409–418
Yang J, Liang H, Hu K, Xiong Z, Cao M, Zhong Z, Deng M (2021) The effects of several postoperative adjuvant therapies for hepatocellular carcinoma patients with microvascular invasion after curative resection: a systematic review and meta-analysis. Cancer Cell Int 21(1):92. https://doi.org/10.1186/s12935-021-01790-6
Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT (2014) Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology 146(7):1691-1700.e1693. https://doi.org/10.1053/j.gastro.2014.02.032
Zha X, Wang F, Wang Y, He S, Jing Y, Wu X, Zhang H (2011) Lactate dehydrogenase B is critical for hyperactive mTOR-mediated tumorigenesis. Cancer Res 71(1):13–18. https://doi.org/10.1158/0008-5472.Can-10-1668
Zhong JH, Li LQ (2010) Postoperative adjuvant transarterial chemoembolization for participants with hepatocellular carcinoma: a meta-analysis. Hepatol Res 40(10):943–953. https://doi.org/10.1111/j.1872-034X.2010.00710.x
Zhong C, Guo RP, Li JQ, Shi M, Wei W, Chen MS, Zhang YQ (2009) A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma. J Cancer Res Clin Oncol 135(10):1437–1445. https://doi.org/10.1007/s00432-009-0588-2
Zhou D, Liang J, Xu LI, He F, Zhou Z, Zhang Y, Chen M (2016) Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. Oncol Lett 11(5):2987–2994. https://doi.org/10.3892/ol.2016.4359
Zhou Q, Deng G, Wang Z, Dai G (2022) Preoperative lung immune prognostic index predicts survival in patients with pancreatic cancer undergoing radical resection. Front Surg 9:1002075. https://doi.org/10.3389/fsurg.2022.1002075
Zuo CH, Xia M, Liu JS, Qiu XX, Lei X, Xu RC, Liu C (2015) Transcatheter arterial chemoembolization combined with interferon-α is safe and effective for patients with hepatocellular carcinoma after curative resection. Asian Pac J Cancer Prev 16(1):245–251. https://doi.org/10.7314/apjcp.2015.16.1.245
Funding
This study was supported by Sichuan Province Science and Technology Support Program (no. 2018HH0062), and Sichuan Province Science and Technology Support Program (no. 2021YFH0187).
Author information
Authors and Affiliations
Contributions
YL and JS were responsible for study conception and design, data acquisition, data analysis and drafting and revision of the manuscript. RY was responsible for data analysis and revision of the manuscript. XH and YS were responsible for study conception and design, data analysis and drafting and revision of the manuscript. DZ, QY, and YS were responsible for data acquisition. All authors reviewed the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that there is no conflict of interest.
Ethics approval and consent to participate
The study was approved by the Human Ethics Committee of Sichuan Cancer Hospital, and written informed consent was obtained from all participants. All procedures were performed in accordance with the ethical guidelines of the Helsinki Declaration.
Patient consent for publication
Not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liang, Y., Yang, R., Shang, J. et al. Lung immune prognostic index‑based nomogram for recurrence of hepatocellular carcinoma after postoperative adjuvant TACE. J Cancer Res Clin Oncol 149, 16461–16471 (2023). https://doi.org/10.1007/s00432-023-05413-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-023-05413-7